![](/img/cover-not-exists.png)
Randomized phase II trial of first-line gefitinib, gemcitabine or docetaxel in performance status (PS) 2 or 3 non-small cell lung cancer (NSCLC) patients (IFCT-0301): elderly patients analysis
G. Des Guetz, V. Westeel, F. Morin, L. Baudrin, V. Gounant, B. Lebeau, F. Vaylet, T. Urban, F. Barlesi, D. Moro-Sibilot, P.J. Souquet, D. Debieuvre, D. Braun, G. Fraboulet, K. Chouahnia, J.F. MorereVolume:
68
Year:
2008
Language:
english
Pages:
1
DOI:
10.1016/s1040-8428(08)70110-0
File:
PDF, 53 KB
english, 2008